Ansgar W Lohse
Rate of Spleen Length Progression Is a Marker of Outcome in Patients With Primary Sclerosing Cholangitis.
Jung F, Cazzagon N, Vettorazzi E, Corpechot C, Chazouillères O, Arrivé L, Lohse A, Schramm C, Ehlken H. Rate of Spleen Length Progression Is a Marker of Outcome in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol 2019; 17:2613-2615.
04.01.2019Rate of Spleen Length Progression Is a Marker of Outcome in Patients With Primary Sclerosing Cholangitis.
04.01.2019Clin Gastroenterol Hepatol 2019; 17:2613-2615
Jung Franziska, Cazzagon Nora, Vettorazzi Eik, Corpechot Christophe, Chazouillères Olivier, Arrivé Lionel, Lohse Ansgar W, Schramm Christoph, Ehlken Hanno
Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis.
Peiseler M, Reiners D, Pinnschmidt H, Sebode M, Jung F, Hartl J, Zenouzi R, Ehlken H, Groth S, Schachschal G, Rösch T, Weiler-Normann C, Lohse A, Schramm C. Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis. PloS one 2018; 13:e0202686.
20.08.2018Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis.
20.08.2018PloS one 2018; 13:e0202686
Peiseler Moritz, Reiners David, Pinnschmidt Hans O, Sebode Marcial, Jung Franziska, Hartl Johannes, Zenouzi Roman, Ehlken Hanno, Groth Stefan, Schachschal Guido, Rösch Thomas, Weiler-Normann Christina, Lohse Ansgar W, Schramm Christoph